A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset… (NCT03729362) | Clinical Trial Compass
CompletedPhase 3
A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease
United States125 participantsStarted 2018-12-04
Plain-language summary
This is a phase 3 double-blind randomized study to study the efficacy and safety of intravenous ATB200 Co-administered with oral AT2221 in adult subjects with Late Onset Pompe Disease compared with Alglucosidase Alfa/placebo.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Subject must provide signed informed consent prior to any study-related procedures being performed.
✓. Male and female subjects are ≥ 18 years old and weigh ≥ 40 kg at screening.
✓. Female subjects of childbearing potential and male subjects must agree to use medically accepted methods of contraception during the study and for 90 days after the last dose of study drug.
✓. Subject must have a diagnosis of LOPD based on documentation of one of the following:
✓. deficiency of GAA enzyme
✓. GAA genotyping
✓. Subject is classified as one of the following with respect to ERT status:
✓. ERT-experienced, defined as currently receiving standard of care ERT (alglucosidase alfa) at the recommended dose and regimen (ie, 20 mg/kg dose every 2 weeks) for ≥ 24 months
Exclusion criteria
✕. Subject has received any investigational therapy or pharmacological treatment for Pompe disease, other than alglucosidase alfa, within 30 days or 5 half-lives of the therapy or treatment, whichever is longer, before Day 1 or is anticipated to do so during the study.
✕. Subject has received gene therapy for Pompe disease
✕. Subject is taking any of the following prohibited medications within 30 days before Day 1:
What they're measuring
1
Change From Baseline to Week 52 in 6 Minute Walk Distance (6MWD)
. Subject requires the use of invasive or noninvasive ventilation support for \> 6 hours per day while awake.
✕. Subject has a hypersensitivity to any of the excipients in ATB200, alglucosidase alfa, or AT2221.
✕. Subject has a medical condition or any other extenuating circumstance that may, in the opinion of the investigator or medical monitor, pose an undue safety risk to the subject or may compromise his/her ability to comply with or adversely impact protocol requirements. This includes clinical depression (as diagnosed by a psychiatrist or other mental health professional) with uncontrolled or poorly controlled symptoms.
✕. Subject, if female, is pregnant or breastfeeding at screening.
✕. Subject, whether male or female, is planning to conceive a child during the study.